Tonix Pharmaceuticals Holding Corp Market Cap ($72.59 Million)
Market Cap & Net Worth: Tonix Pharmaceuticals Holding Corp (TNXP)
Tonix Pharmaceuticals Holding Corp market cap. Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has a market capitalization of $72.59 Million ($72.59 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20275 globally and #4631 in its home market, demonstrating a -5.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tonix Pharmaceuticals Holding Corp's stock price $5.11 by its total outstanding shares 14205401 (14.21 Million). Also see cash efficiency ratio of Tonix Pharmaceuticals Holding Corp for how efficiently the company converts equity into cash flow.
Tonix Pharmaceuticals Holding Corp Market Cap History (2015–2026)
Tonix Pharmaceuticals Holding Corp market cap history from 2015 to 2026. Data shows change from $14.21 Trillion to $72.59 Million (-66.79% CAGR). Check Tonix Pharmaceuticals Holding Corp (TNXP) share price today for real-time trading data and today's change.
Index Memberships
Tonix Pharmaceuticals Holding Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #567 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1943 of 3165 |
Weight: Tonix Pharmaceuticals Holding Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tonix Pharmaceuticals Holding Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tonix Pharmaceuticals Holding Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Tonix Pharmaceuticals Holding Corp (TNXP) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
16.93x
Tonix Pharmaceuticals Holding Corp's market cap is 16.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $61.37 Billion | $2.91 Million | -$50.39 Million | 21059.48x | N/A |
| 2022 | $1.11 Billion | $9.03 Million | -$115.00 Million | 122.68x | N/A |
| 2023 | $183.19 Million | $7.77 Million | -$116.66 Million | 23.58x | N/A |
| 2024 | $4.68 Million | $10.09 Million | -$130.04 Million | 0.46x | N/A |
| 2025 | $221.89 Million | $13.11 Million | -$124.02 Million | 16.93x | N/A |
Competitor Companies of TNXP by Market Capitalization
Companies near Tonix Pharmaceuticals Holding Corp in the global market cap rankings as of November 5, 2026. Also see TNXP total assets for a full breakdown of the balance sheet.
Key companies related to Tonix Pharmaceuticals Holding Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Tonix Pharmaceuticals Holding Corp (2015–2026)
Market capitalization of Tonix Pharmaceuticals Holding Corp from 2015 to today. Between 2015 and today, Tonix Pharmaceuticals Holding Corp's market cap moved from $14.21 Trillion to $ 72.59 Million, with a yearly change of -66.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $72.59 Million | -67.29% |
| 2025 | $221.89 Million | +4636.20% |
| 2024 | $4.68 Million | -97.44% |
| 2023 | $183.19 Million | -83.46% |
| 2022 | $1.11 Billion | -96.59% |
| 2021 | $32.52 Billion | -47.01% |
| 2020 | $61.37 Billion | -42.31% |
| 2019 | $106.37 Billion | -94.68% |
| 2018 | $2.00 Trillion | -85.92% |
| 2017 | $14.21 Trillion | 0.00% |
| 2016 | $14.21 Trillion | 0.00% |
| 2015 | $14.21 Trillion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Tonix Pharmaceuticals Holding Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $72.59 Million USD |
| MoneyControl | $72.59 Million USD |
| MarketWatch | $72.59 Million USD |
| marketcap.company | $72.59 Million USD |
| Reuters | $72.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and T… Read more